Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis

Br J Dermatol. 2000 May;142(5):985-90. doi: 10.1046/j.1365-2133.2000.03483.x.

Abstract

A double blind left, right comparative study was carried out in 17 psoriatic subjects to examine the influence of a topically applied inhibitor of nitric oxide (NO) synthesis on the pathogenic events of psoriasis. The inhibitor NG-monomethyl-L-arginine (L-NMMA) in aqueous cream BP was applied to one plaque while aqueous cream BP alone served as control. Compared with the control, the L-NMMA-treated side showed significant (77%) inhibition of NO production and a reduction in blood flow, confirming its bioavailability. L-NMMA significantly reduced staining for endothelial cells and intercellular adhesion molecule 1, while CD1a-positive Langerhans cells and CD8-positive suppressor cytotoxic T cells increased. CD4-positive lymphocytes and epidermal proliferation, as indicated by Ki-67 staining, were unaffected by this degree of inhibition of NO synthesis, and correspondingly significant clinical improvement was not found.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Biological Availability
  • CD4-Positive T-Lymphocytes / drug effects
  • Cell Division / drug effects
  • Double-Blind Method
  • Endothelium / cytology
  • Enzyme Inhibitors / pharmacokinetics
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide Synthase / antagonists & inhibitors*
  • Nitric Oxide Synthase / therapeutic use
  • Psoriasis / drug therapy*
  • Psoriasis / enzymology
  • Psoriasis / physiopathology
  • Regional Blood Flow / drug effects
  • Treatment Outcome
  • omega-N-Methylarginine / pharmacokinetics
  • omega-N-Methylarginine / therapeutic use*

Substances

  • Enzyme Inhibitors
  • omega-N-Methylarginine
  • Nitric Oxide Synthase